Navigation Links
ThromboGenics N.V.: Business Update
Date:11/6/2008

enics announced that a group of

private investors based in Belgium had together acquired an 8% stake in

the Company. This stake was purchased from Biggar Limited, a charitable

foundation that is ThromboGenics' largest single shareholder. Biggar

now holds a 9.8% stake in ThromboGenics, and has informed the Company

that it intends to remain an important shareholder in ThromboGenics for

the long term.

- ThromboGenics shares entered the Bel Mid Index on 1 October

2008, following the quarterly review of the Belgian indices by

Euronext. The elevation of ThromboGenics to the Bel Mid Index reflects

the significant progress that the Company has made since its IPO in

2006.

Corporate Update

- On 1 September, Patrik De Haes, MD, formerly the Company's

Chief Operating Officer, was appointed to succeed Professor Desire

Collen as the Company's new Chief Executive Officer. Dr. De Haes will

be proposed to become a member of the Board of Directors of

ThromboGenics at the next General Meeting. In the meantime, he will be

invited to participate in Board meetings.

ThromboGenics will continue to benefit from Professor Collen's significant scientific and drug discovery knowledge. Professor Collen will remain Chairman of ThromboGenics' Board of Directors.

Pipeline Update

Microplasmin in Eye Disease

ThromboGenics is working to finalise its Phase III clinical trial program for microplasmin in the treatment of back of the eye disease, following a successful End of Phase II meeting with the FDA. The initial indication planned for the program is the nonsurgical resolution of vitreomacular adhesion. Two placebo controlled trials are planned, one in the U.S. and one combined European and North American trial. Together it is anticipated that the two trials will recruit a total of approximately 640 patients, with the first trial ex
'/>"/>

SOURCE ThromboGenics NV
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. ThromboGenics Announces Half Year Results 2008
2. ThromboGenics Appoints Dr. Patrik De Haes as Chief Executive Officer
3. ThromboGenics Announces Private Investors Acquire 8% Stake in the Company
4. ThromboGenics and BioInvent Announce a Strategic Alliance With Roche for TB-403, a Novel Anti-Cancer Antibody
5. ThromboGenics N.V. - Business Update
6. ThromboGenics Completes Patient Enrolment of MITI IV Trial, a Phase II Study Evaluating the Safety and Preliminary Efficacy of Microplasmin in the Treatment of Acute Stroke
7. ThromboGenics Announces 2007 Full Year Results
8. ThromboGenics and BioInvent Receive Approval to Begin Clinical Trials of TB-403 for the Treatment of Cancer
9. ThromboGenics Presents Results of the Phase I Trial of TB-402 at the Prestigious American Society of Hematology Annual Meeting
10. ThromboGenics Presents Results of the Vitreomacular Traction Trial (MIVI IIT) at the American Society of Retina Specialists Annual Meeting
11. ThromboGenics and BioInvent Announce Publication of Exciting Data on a Novel Class of Angiogenesis Inhibitors in Cell
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 The UPMC Center ... 2015 Fellows in the Emerging Leaders in Biosecurity Initiative ... leaders in the field of biosecurity, UPMC has selected ... a wide array of backgrounds, including biological science, medicine, ... "With the vision and support of ...
(Date:3/4/2015)... , Mar. 04, 2015 Research and Markets ... addition of the "Global Biologics and Biosimilars ... , The Global Biologics and ... in-depth study on the current state of the ... provides a basic overview of the industry including ...
(Date:3/4/2015)... CITY, Calif. , March 4, 2015 /PRNewswire/ ... ), a specialty pharmaceutical company focused on the ... treatment of acute and breakthrough pain, today announced ... 2014 financial results after market close on Monday, ... investment-community conference call at 4:30 p.m. Eastern Time ...
(Date:3/4/2015)... 4, 2015 Launched by ... in December 2011, ,SARAH, - the ... microspheres versus sorafenib in advanced hepatocellular carcinoma (HCC) has ...   SARAH, a large French study of ... or HCC) has completed patient enrolment, exceeding its 400-patient ...
Breaking Biology Technology:UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 2UPMC Center for Health Security Announces 2015 Emerging Leaders in Biosecurity 3Global Biologics and Biosimilars Industry Report 2015-2020 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 2AcelRx Pharmaceuticals to Hold Annual 2014 Financial Results Conference Call and Webcast on Monday, March 9th, 2015 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 2Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 3Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 4Treatment of Primary Liver Cancer: SARAH Study Completes Enrolment, Results Expected Late 2016 5
... Wis. -- Research scientist Seth Dobrin, Ph.D., has been ... Mammalian Genotyping Service of the Marshfield Clinic Research Foundation. , ... research to problems of mental health and development of new ... on discoveries he made earlier in his career as well ...
... SkyCable in Madison could be a gain for TDS Telecom ... as soon as it can get FCC approval. , ,"We've not ... DeAnne Boegli. She emphasized that TDS did not purchase SkyCable ... extends 35 miles out of Madison from a shared communications tower ...
... . -- Oshkosh Truck Corp . and partners ... that their robotic truck, TerraMax, qualified late Wednesday to compete ... of unmanned vehicles across the Mojave Desert on Saturday, Oct. ... of 2.2- and 2.9-mile qualifying obstacle courses at the California ...
Cached Biology Technology:Demise of SkyCable is opportunity for TDS Telecom 2Oshkosh's robotic truck qualifies for DARPA challenge 2
(Date:2/12/2015)... Minn. , Feb. 12, 2015   ... company specializing in clinical study management systems, has ... Program , further distinguishing iMedNet ... Clinical Research Organizations (CROs) and healthcare consultants.  Building ... support, prospective customer referrals and numerous co-marketing opportunities), ...
(Date:2/9/2015)... 2015  Lintec of America recently announced an exclusive ... (CNT) macrostructures, including sheets, yarns and ribbons, developed at ... Leveraging the vast industrial resources of the global Lintec ... Lintec of America is forming the Nano-Science and Technology ... focusing on scaling up the manufacturing and commercialization of ...
(Date:2/5/2015)... 2015 NXT-ID, Inc. (NASDAQ: NXTD ... company focused on the growing mobile commerce market, announces ... ) as part of its 2015 marketing and branding ... its new consumer website for Wocketwallet.com earlier this month. ... NXT-ID said, "Our new corporate website naturally showcases our ...
Breaking Biology News(10 mins):MedNet Solutions Announces Key Enhancements To Its iMedNet Partner Program 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 2NXT-ID, Inc. Launches New Corporate Website As Part Of Ongoing 2015 Branding Initiatives For Wocket Smart Wallet 3
... genes are especially challenging because they combine many ... of non-coding elements (introns). During processing, introns are ... a template for proteins called messenger RNA (mRNA). ... of a functional protein or, worse, produce an ...
... Institute of Dental and Craniofacial Research (NIDCR), part of ... new piece to the puzzle of how tumor cells ... abnormal growth, a well-known process called angiogenesis. , As ... Cell, the scientists found that in addition to the ...
... cancer that is based on infection with a specially designed ... has shown promise in clinical trials. Now, new research suggests ... as well. The study, published in the July issue of ... to viral therapy after they have been incubated at an ...
Cached Biology News:Carnegie Mellon University research reveals how cells process large genes 2Carnegie Mellon University research reveals how cells process large genes 3New lead reported in tumor angiogenesis 2New lead reported in tumor angiogenesis 3Elevated temperature enhances success of viral cancer therapy 2
Defender against cell death 1...
Human Osteocalcin (1-22) mature form. Also reacts with Osteocalcin (1-44) and Osteocalcin (1-49). No reactivity with Bone sialoprotein....
HSV-1 gE Envelope Protein (9H3)...
Mouse monoclonal [B314.1 (MAC 387)] to Macrophage L1 protein Calprotectin (rating: ****) ( Abpromise for all tested applications)....
Biology Products: